Curcumin + piperine
Curcumin + piperine has been studied in 8 papers since 2018: 1 trial in people, 1 in animals, 6 reviews; 3 in the past year. The newest paper, Nov 16, 2026: “The efficacy of non-pharmacological interventions on non-alcoholic fatty liver disease in adults: An umbrella meta-analysis”.
8 papers study it15 findingsUpdated
1 new paper in 30 daysSee all 8 papers on curcumin + piperine
At a glance
Independent labs found the same change in people. 5 independent labs in 5 countries.
“Curcumin + piperine decreased waist circumference (p = 0.026), systolic blood pressure (p = 0.001), total cholesterol (p = 0.004), low-density lipoprotein-cholesterol (p = 0.006), FBG (p = 0.002)”
None of its findings points the other way.
- 5 independent labs in 5 countries
- Funders: National Institute for Medical Research Development and 5 more
- 2 of 14 findings with company ties
- Human trial1
- Animals1
Studies in people
1 study gave curcumin + piperine to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases waist circumferencep = 0.026 down: Decreases systolic blood pressurep = 0.001 down: Decreases total cholesterolp = 0.004 | Randomized trial12 weeks | In NAFLD patients with moderate-to-high hepatic steatosis | Phytotherapy research : PTR, Feb 17, 2023 |
What did studies of curcumin + piperine find?
14Studies of curcumin + piperine measured 14 outcomes, among them total cholesterol, flare-free survival and inflammation.
Total cholesterol
downin humans2
2 studies
Total cholesterol
downin humans2
Curcumin + piperine decreases total cholesterol in NAFLD patients with moderate-to-high hepatic steatosis (p = 0.004).
Human trialin NAFLD patients with moderate-to-high hepatic steatosis500 mg/day curcumin plus 5 mg/day piperine12 weeks
Curcumin + piperine decreases total cholesterol in patients suffering from metabolic syndrome.
Reviewin patients suffering from metabolic syndrome
Flare-free survival
no changein humans1
1 study
Flare-free survival
no changein humans1
Curcumin + piperine showed no clear effect on flare-free survival in phase III rheumatoid arthritis maintenance trial.
Reviewin phase III rheumatoid arthritis maintenance trial
Inflammation
downin humans1
1 study
Inflammation
downin humans1
Curcumin + piperine decreases inflammation in humans.
Reviewacross metabolic syndrome, type 2 diabetes, hemodialysis, inflammatory bowel disease, CABG recovery, and sepsis
Bioavailability
upin reviews1
1 study
Bioavailability
upin reviews1
Curcumin + piperine increases bioavailability (up to 20-fold).
Review
Body mass index
no changein humans1
1 study
Body mass index
no changein humans1
Curcumin + piperine showed no clear effect on body mass index in patients with prediabetes and type 2 diabetes mellitus (MD = -0.41, 95% CI [-0.85 to 0.03], p = 0.07).
Reviewin patients with prediabetes and type 2 diabetes mellitus
HOMA-IR
no changein humans1
1 study
HOMA-IR
no changein humans1
Curcumin + piperine showed no clear effect on HOMA-IR in patients with prediabetes and type 2 diabetes mellitus (MD = -0.36, 95% CI [-0.77 to 0.05], p = 0.09).
Reviewin patients with prediabetes and type 2 diabetes mellitus
Fasting plasma glucose
no changein humans1
1 study
Fasting plasma glucose
no changein humans1
Curcumin + piperine showed no clear effect on fasting plasma glucose in patients with prediabetes and type 2 diabetes mellitus (MD = -7.61, 95% CI [-15.26, 0.03], p = 0.05).
Reviewin patients with prediabetes and type 2 diabetes mellitus
Liver stiffness
no changein humans1
1 study
Liver stiffness
no changein humans1
Curcumin + piperine showed no clear effect on liver stiffness in NAFLD patients with moderate-to-high hepatic steatosis (p > 0.05).
Human trialin NAFLD patients with moderate-to-high hepatic steatosis500 mg/day curcumin plus 5 mg/day piperine12 weeks
Alanine transaminase
downin humans1
1 study
Alanine transaminase
downin humans1
Curcumin + piperine decreases alanine transaminase in NAFLD patients with moderate-to-high hepatic steatosis (p = 0.007).
Human trialin NAFLD patients with moderate-to-high hepatic steatosis500 mg/day curcumin plus 5 mg/day piperine12 weeks
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Curcumin + piperine decreases systolic blood pressure in NAFLD patients with moderate-to-high hepatic steatosis (p = 0.001).
Human trialin NAFLD patients with moderate-to-high hepatic steatosis500 mg/day curcumin plus 5 mg/day piperine12 weeks
Waist circumference
downin humans1
1 study
Waist circumference
downin humans1
Curcumin + piperine decreases waist circumference in NAFLD patients with moderate-to-high hepatic steatosis (p = 0.026).
Human trialin NAFLD patients with moderate-to-high hepatic steatosis500 mg/day curcumin plus 5 mg/day piperine12 weeks